Compare Abbott Laboratories (ABT) vs Ally Financial Inc (ALLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Ally Financial Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Ally Financial Inc trades at $44.33 (market cap $13.92B). The key difference: Abbott Laboratories is far larger — about 12× Ally Financial Inc's market cap, and Ally Financial Inc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| ABT | ALLY | |
|---|---|---|
Market Cap | $166.94B | $13.92B |
Sector | Health | Financials |
52-Week High | $136.62 | $47.25 |
52-Week Low | $82.57 | $35.96 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Ally Financial (ALLY) trades at $45.40, up 0.18% with strong analyst support (68% buy ratings) and a $54 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q3 2025-Q1 2026. Fundamentals remain solid with a P/E of 11.22 and net income margin of 14.9%, though revenue has declined from $9.2B in 2022 to $8.77B in 2025. Recent corporate developments include a $0.30 dividend payment and upcoming Q2 2026 earnings release on July 21, 2026.
ALLY presents a compelling value opportunity with attractive valuation metrics and consistent earnings outperformance. The primary investment thesis centers on the company's dominant auto lending position and shareholder returns via dividends. Key risks include revenue stagnation, macroeconomic sensitivity to interest rates, and competitive pressure from digital banking disruptors. Upside potential exists if Q2 2026 earnings meet or exceed the $1.26 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
